In this issue of Blood, Basiorka et al have challenged how we think about cell death in myelodysplastic syndromes (MDS), proposed an explanation for the shared morphologic changes that are seen despite genetic heterogeneity, and identified a new target for therapeutic intervention.(1)
展开▼